US, Europe, And MENA Expansion Will Boost Global Pharmaceutical Demand
Hikma Pharmaceuticals’ Future P/E ratio has dropped sharply, indicating improved valuation relative to earnings expectations, while revenue growth forecasts remain steady, resulting in the consensus price target edging down slightly from £25.17 to £25.02.
What's in the News
- Hikma maintained full-year 2025 group revenue growth guidance of 4–6%, with core operating profit expected at $730–770 million; injectable segment revenue growth is guided at 7–9%, branded revenue at 6–7%, and Rx revenue broadly flat versus 2024.
- Core operating margin guidance was lowered to 32–33% (from mid-30s), citing Euro appreciation and mild inflation in shipping/expenses; branded segment core margin is seen near 25%, driven by a favorable product mix and new launches; Rx core margin is expected at ~16%.
- The company recommended an interim dividend of 36 cents per share, up from 32 cents per share in the first half of 2024.
- FDA approved TYZAVAN™, a ready-to-infuse vancomycin injection, eliminating the need for compounding or refrigeration and simplifying hospital workflows, targeting faster and safer sepsis treatment; US vancomycin injection sales approached $200 million in 2024.
Valuation Changes
Summary of Valuation Changes for Hikma Pharmaceuticals
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from £25.17 to £25.02.
- The Future P/E for Hikma Pharmaceuticals has significantly fallen from 15.34x to 11.36x.
- The Consensus Revenue Growth forecasts for Hikma Pharmaceuticals remained effectively unchanged, at 6.0% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.